PT - JOURNAL ARTICLE AU - Kobayashi, Takaaki AU - Nishina, Yuka AU - Tomoi, Hana AU - Harada, Ko AU - Tanaka, Kyuto AU - Matsumoto, Eiyu AU - Horimukai, Kenta AU - Ishihara, Jun AU - Sasaki, Shugo AU - Inaba, Kanako AU - Seguchi, Kyosuke AU - Takahashi, Hiromizu AU - Salinas, Jorge L. AU - Yamada, Yuji TI - Corowa-kun: Impact of a COVID-19 vaccine information chatbot on vaccine hesitancy, Japan 2021 AID - 10.1101/2021.05.26.21257854 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.26.21257854 4099 - http://medrxiv.org/content/early/2021/05/30/2021.05.26.21257854.short 4100 - http://medrxiv.org/content/early/2021/05/30/2021.05.26.21257854.full AB - Background Few studies have assessed how mobile messenger apps affect COVID-19 vaccine hesitancy. We created a COVID-19 vaccine information chatbot in a popular messenger app in Japan to answer commonly asked questions.Methods LINE is the most popular messenger app in Japan. Corowa-kun, a free chatbot, was created in LINE on February 6, 2021. Corowa-kun provides instant, automated answers to frequently asked COVID-19 vaccine questions. In addition, a cross-sectional survey assessing COVID-19 vaccine hesitancy was conducted via Corowa-kun during April 5–12, 2021.Results A total of 59,676 persons used Corowa-kun during February–April 2021. Of them, 10,192 users (17%) participated in the survey. Median age was 55 years (range 16–97), and most were female (74%). Intention to receive a COVID-19 vaccine increased from 59% to 80% after using Corowa-kun (p < 0.01). Overall, 20% remained hesitant: 16% (1,675) were unsure, and 4% (364) did not intend to be vaccinated. Factors associated with vaccine hesitancy were: age 16 to 34 (odds ratio [OR] = 3.7, 95% confidential interval [CI]: 3.0–4.6, compared to age ≥65), female sex (OR = 2.4, Cl: 2.1–2.8), and history of a previous vaccine side-effect (OR = 2.5, Cl: 2.2–2.9). Being a physician (OR = 0.2, Cl: 0.1–0.4) and having received a flu vaccine the prior season (OR = 0.4, Cl: 0.3–0.4) were protective.Conclusions Corowa-kun reduced vaccine hesitancy by providing COVID-19 vaccine information in a messenger app. Mobile messenger apps could be leveraged to increase COVID-19 vaccine acceptance.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board of Kanto Central Hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, [T.K], upon reasonable request.